Curis Prepares for Major Presentations at SNO Meeting
LEXINGTON, Mass. — Curis, Inc. (NASDAQ: CRIS) is excited to share that the company will participate in the prestigious 30th Annual Meeting of the Society for Neuro-Oncology (SNO). This event is taking place soon, and Curis intends to showcase significant clinical data regarding emavusertib (CA-4948), a promising small molecule IRAK4 inhibitor developed by the company. The focus will be on its efficacy and safety in treating Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL).
Details of the Presentations
Curis plans to present updates on its ongoing research and findings from the emavusertib trials. Notably, they will detail three distinct presentations and an oral segment dedicated to the preclinical phases of emavusertib. These sharing stages are instrumental in enhancing the understanding of the drug's potential effects on CNS lymphomas.
Presentation Schedule
The first presentation is set for November 21. At 4:30 PM ET, Dr. Christian Grommes from the Memorial Sloan Kettering Cancer Center will address attendees, focusing on the Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination.
Following this on November 22 at 4:45 PM ET, Dr. Grommes will again take the stage, this time presenting on the safety and efficacy of emavusertib combined with Ibrutinib in relapsed or refractory patients. The title of this presentation will be Preliminary Safety and Efficacy of Emavusertib (CA-4948) in Combination with Ibrutinib in Relapsed/Refractory Primary Central Nervous System Lymphoma Patients.
Future Insights on Emavusertib
Concluding the presentations, Dr. Christina von Roemeling from the University of Florida will present on November 23 at 3:24 PM ET. Her topic, Targeting Myddosome Signaling to Improve Immunotherapy in Melanoma Brain Metastases, will delve into innovative approaches in cancer treatment.
About Emavusertib and its Clinical Trials
Emavusertib is currently under scrutiny in various studies, including the TakeAim Lymphoma Phase 1/2 study, aimed at patients with PCNSL. Here, it operates alongside the BTK inhibitor ibrutinib, targeting those who have had limited success with previous treatments. In addition, emavusertib is being examined in studies involving patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome, demonstrating its versatility across different types of cancer.
Curis holds the exclusive rights to emavusertib through a collaboration with Aurigene Discovery Technologies Limited and has made significant strides in the drug's development. Furthermore, emavusertib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for its use in treating PCNSL, AML, and MDS, highlighting the drug's potential impact on patient populations.
Curis has a history of significant collaborations, including licensing their rights to Erivedge® to Genentech, which is now commercializing the drug effectively for advanced basal cell carcinoma treatment.
Frequently Asked Questions
What is the focus of Curis's research presentations?
Curis is focusing on its investigational drug emavusertib, particularly its effectiveness and safety in treating CNS lymphomas.
When will the presentations take place?
The presentations are scheduled from November 21 to November 23 during the SNO meeting.
Who are the key presenters for Curis?
Key presenters include Dr. Christian Grommes and Dr. Christina von Roemeling.
What type of data will Curis present?
Curis will present clinical and preclinical data regarding emavusertib and its use in combination with other therapies.
What are the future plans for emavusertib?
Curis aims to further evaluate emavusertib across various cancers, enhancing treatment options for patients facing relapsed diseases.
